US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Pliant Therapeutics Inc (PLRX)
Pliant Therapeutics Inc (PLRX) ニュース

PLRX

Pliant Therapeutics (PLRX)

Pliant Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:PLRX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/02	22 : 00	GlobeNewswire Inc.	Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/11/21	22 : 00	GlobeNewswire Inc.	Pliant Therapeutics to Participate in Upcoming Investor Events	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/11/19	08 : 00	GlobeNewswire Inc.	Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/11/15	07 : 05	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/11/08	06 : 17	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/11/08	06 : 14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/11/08	06 : 05	GlobeNewswire Inc.	Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/11/06	22 : 00	GlobeNewswire Inc.	Pliant Therapeutics to Participate in the Stifel Healthcare Conference	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/10/17	21 : 00	GlobeNewswire Inc.	Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/10/05	06 : 34	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/10/02	05 : 35	GlobeNewswire Inc.	Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/10/01	05 : 45	GlobeNewswire Inc.	Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/09/28	05 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/09/24	21 : 00	GlobeNewswire Inc.	Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/09/10	21 : 00	GlobeNewswire Inc.	Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/08/28	21 : 00	GlobeNewswire Inc.	Pliant Therapeutics to Participate in Upcoming Investor Events	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/08/28	21 : 00	GlobeNewswire Inc.	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/08/26	22 : 10	GlobeNewswire Inc.	Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/08/08	05 : 13	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/08/08	05 : 08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/08/08	05 : 05	GlobeNewswire Inc.	Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/08/07	05 : 03	GlobeNewswire Inc.	Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/07/16	00 : 54	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/07/15	21 : 00	GlobeNewswire Inc.	Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/07/13	07 : 37	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/07/13	07 : 22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/07/13	07 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/07/12	05 : 54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/07/12	05 : 47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PLRX	Pliant Therapeutics Inc
2024/07/12	05 : 41	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PLRX	Pliant Therapeutics Inc

Showing the most relevant articles for your search:NASDAQ:PLRX

1 2 3 4 5 6 7 8 9 10 次へ >>

Invesco QQQ Trust Series 1

American Express

Bank of America

Financial Select Sector

US Dollar vs Yen

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約